written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license (i.e., a completed Application for License to Public Health Service Inventions) in the indicated exclusive field of use filed in response to this notice will be treated as objections to the grant of the contemplated license. Comments and objections will not be made available for public inspection and, to the extent permitted by law, will not be subject to disclosure under the Freedom of Information Act 35 U.S.C. 552.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.

APPLICATIONS: The Use of Geldanamycin and Derivatives for the Treatment of Cancer

AGENCY: National Institutes of Health, Department of Health and Human Services.